Biomedicines (Aug 2022)

Clinical Predictors of Lung-Function Decline in Systemic-Sclerosis-Associated Interstitial Lung Disease Patients with Normal Spirometry

  • Tamas Nagy,
  • Nora Melinda Toth,
  • Erik Palmer,
  • Lorinc Polivka,
  • Balazs Csoma,
  • Alexandra Nagy,
  • Noémi Eszes,
  • Krisztina Vincze,
  • Enikő Bárczi,
  • Anikó Bohács,
  • Ádám Domonkos Tárnoki,
  • Dávid László Tárnoki,
  • György Nagy,
  • Emese Kiss,
  • Pál Maurovich-Horvát,
  • Veronika Müller

DOI
https://doi.org/10.3390/biomedicines10092129
Journal volume & issue
Vol. 10, no. 9
p. 2129

Abstract

Read online

Interstitial lung disease (ILD) is the leading cause of mortality in systemic sclerosis (SSc). Progressive pulmonary fibrosis (PPF) is defined as progression in 2 domains including clinical, radiological or lung-function parameters. Our aim was to assess predictors of functional decline in SSc-ILD patients and compare disease behavior to that in idiopathic pulmonary fibrosis (IPF) patients. Patients with normal forced vital capacity (FVC > 80% predicted; SSc-ILD: n = 31; IPF: n = 53) were followed for at least 1 year. Predictors of functional decline including clinical symptoms, comorbidities, lung-function values, high-resolution CT pattern, and treatment data were analyzed. SSc-ILD patents were significantly younger (59.8 ± 13.1) and more often women (93 %) than IPF patients. The median yearly FVC decline was similar in both groups (SSc-ILD = −67.5 and IPF = −65.3 mL/year). A total of 11 SSc-ILD patients met the PPF criteria for functional deterioration, presenting an FVC decline of −153.9 mL/year. Cough and pulmonary hypertension were significant prognostic factors for SSc-ILD functional progression. SSc-ILD patients with normal initial spirometry presenting with cough and PH are at higher risk for showing progressive functional decline.

Keywords